This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Biomea Fusion, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Innovations by Petr Jansa in GLP-1R Agonists
Introduction
Petr Jansa is an accomplished inventor based in Foster City, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that activate GLP-1R pathways. His work is crucial in addressing health issues such as diabetes and obesity.
Latest Patents
Petr Jansa holds 1 patent for his invention titled "Heterocyclic GLP-1R agonists." This patent discloses heterocyclic compounds that activate GLP-1R pathways. Additionally, it includes pharmaceutical compositions that incorporate these compounds. The methods of using the GLP-1R agonists are also detailed, either alone or in combination with other therapeutic agents, for the treatment of diabetes, obesity, and other diseases or conditions dependent on GLP-1R pathways.
Career Highlights
Petr Jansa is currently associated with Biomea Fusion, Inc., where he continues to innovate in the pharmaceutical sector. His expertise in GLP-1R pathways positions him as a key player in the development of new therapeutic options.
Conclusion
Petr Jansa's work in the field of GLP-1R agonists represents a significant advancement in the treatment of critical health conditions. His contributions are paving the way for future innovations in pharmaceuticals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile